TIANYU PHARM issued a profit forecast, expecting a net profit attributable to the parent company of 130 million to 180 million yuan in the first half of the year, a year-on-year increase of 144.29%-238.25%
I'm LongbridgeAI, I can summarize articles.TIANYU PHARM expects its net profit attributable to shareholders in the first half of 2025 to be between 130 million yuan and 180 million yuan, a year-on-year increase of 144.29%-238.25%. The net profit after deducting non-recurring gains and losses is expected to be between 121 million yuan and 171 million yuan, a year-on-year increase of 92.79%-172.45%. The company has improved the revenue scale and gross profit growth of its non-sartan active pharmaceutical ingredients and intermediates business, CDMO business, and formulation business through measures such as optimizing product structure, improving market layout, and strengthening cost control
According to the Zhitong Finance APP, TIANYU PHARM (300702.SZ) disclosed its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of the listed company to be between 130 million yuan and 180 million yuan, a year-on-year increase of 144.29%-238.25%; the net profit after deducting non-recurring gains and losses is expected to be between 121 million yuan and 171 million yuan, a year-on-year increase of 92.79%-172.45%.
During the reporting period, the company effectively enhanced the revenue scale and gross profit growth of its non-sartan raw materials and intermediates business, CDMO business, and formulation business through measures such as optimizing product structure, improving market layout, and strengthening cost control